Treatment of Severe Decompensated Heart Failure With High-Dose Intravenous Nitroglycerin: A Feasibility and Outcome Analysis
|
|
- Tobias Norman
- 8 years ago
- Views:
Transcription
1 CARDIOLOGY/ORIGINAL RESEARCH Treatment of Severe Decompensated Heart Failure With High-Dose Intravenous Nitroglycerin: A Feasibility and Outcome Analysis Phillip Levy, MD, MPH Scott Compton, PhD Robert Welch, MD, MS George Delgado, PharmD Alison Jennett, PharmD Neelima Penugonda, MD Robert Dunne, MD Robert Zalenski, MD From the Department of Emergency Medicine, Wayne State University, Detroit, MI. Study objective: We perform a feasibility and outcome assessment of the treatment of severe decompensated heart failure with high-dose nitroglycerin. Methods: This study was designed as a nonrandomized, open-label, single-arm study of high-dose nitroglycerin. Patients with hypertension (systolic blood pressure 160 mm Hg or mean arterial pressure 120 mm Hg) who were refractory to initial therapy were eligible for inclusion. Enrolled patients began receiving a titratable nitroglycerin infusion and were given a bolus of high-dose nitroglycerin (2 mg). Repeated administration of high-dose nitroglycerin was allowed every 3 minutes, up to a total of 10 doses. Predefined effectiveness and safety outcomes were tracked throughout hospital admission. To provide a frame of reference for these outcomes, data were retrospectively compiled for similar patients with severe decompensated heart failure who did not receive high-dose nitroglycerin. Results: Twenty-nine patients received high-dose nitroglycerin. Endotracheal intubation was required in 13.8% of patients, bilevel positive airway pressure (BiPAP) ventilation in 6.9%, and ICU admission in 37.9%. Symptomatic hypotension developed in 1 patient (3.4%), and biomarker evidence of myocardial infarction was found in 17.2% of patients. The mean dose of high-dose nitroglycerin was 6.5 mg ( 3.4). For patients who were treated without high-dose nitroglycerin (n 45), endotracheal intubation occurred in 26.7%, BiPAP in 20.0%, and ICU admission in 80.0%. None of these patients developed symptomatic hypotension, and biomarker evidence of myocardial infarction was observed in 28.9% of patients. Conclusion: In this nonrandomized, open-label trial, high-dose nitroglycerin was associated with endotracheal intubation, BiPAP, and ICU admission less frequently than expected to occur without high-dose nitroglycerin, and adverse events were uncommon. Treatment of hypertensive, severely decompensated heart failure patients with high-dose nitroglycerin seems promising, but a randomized, blinded study is needed to more completely define its clinical utility. According to this trial, such a study seems feasible. [Ann Emerg Med. 2007;50: ] /$-see front matter Copyright 2007 by the American College of Emergency Physicians. doi: /j.annemergmed INTRODUCTION Background Severe decompensated heart failure is a highly lethal condition, with an associated mortality rate of close to 15% 1,2 during the immediate treatment period and 34% at 1 year. In nearly two thirds of these patients, the presenting clinical profile is one of hypertensive crisis, with an increase in systemic vascular resistance, resulting in reduced cardiac output through a transient exacerbation of underlying diastolic or systolic dysfunction. 3-7 In accordance, standard recommended 144 Annals of Emergency Medicine Volume 50, NO. 2 : August 2007
2 Levy et al Severe Decompensated Heart Failure Treated With Intravenous Nitroglycerin Editor s Capsule Summary What is already known on this topic Occasional reports have suggested that high-dose intravenous nitrates can be safe and effective in patients with decompensated heart failure. What question this study addressed Can emergency department patients with severe decompensated heart failure be safely and effectively treated with repeated 2-mg boluses of intravenous nitroglycerin? What this study adds to our knowledge In this 29-patient nonrandomized open-label trial, the mean dose of nitroglycerin was 6.5 mg. Adverse effects were few, and outcomes appeared comparable to or better than those observed in historical controls. How this might change clinical practice High-dose intravenous nitroglycerin seems promising in the treatment of severe decompensated heart failure; however, randomized trials are needed to confirm and quantify the benefit. treatment regimens, such as those offered by the American Heart Association and the European Society of Cardiology, center on the use of vasodilating medications and diuretics to 8-10 provide preload and afterload reduction. In 20% to 40% of patients treated, however, conventional therapy is inadequate, resulting in respiratory failure and the need for accessory ventilatory support. 1,11-13 Importance Early use of intravenous vasoactive medications can have significant impact on the hospital course of patients admitted 1,14,15 with decompensated heart failure. Nitrates (either nitroglycerin or isosorbide dinitrate) have been shown to produce a substantial decrease in pulmonary artery pressure (30% to 50%) and significant clinical improvement in most individuals with decompensated heart failure, but their use at standard doses may be inadequate for those with severe respiratory distress. 6,8,9,16-19 Recent evidence suggests an association between the use of high-dose nitrates and improved clinical outcomes, but the overall reported experience is limited. 18,20-23 Goals of This Investigation The primary objective of this study was to investigate clinically important outcomes associated with addition of high-dose nitroglycerin to standard therapy for the treatment of severe decompensated heart failure. Specifically, we sought to ascertain the following 2 critical event rates in the treatment of eligible patients: (1) the rates of the primary outcome variable of endotracheal intubation with and without high-dose nitroglycerin therapy and (2) the incidence of adverse effects associated with use of high-dose nitroglycerin. Additionally, a general assessment of feasibility was sought according to our ability to enroll patients who met eligibility criteria for the clinical trial. MATERIALS AND METHODS Setting and Selection of Participants Detroit Receiving Hospital and Sinai-Grace Hospital are tertiary care facilities operating within a large urban environment and are affiliated with the Wayne State University School of Medicine. The emergency departments (EDs) have a combined annual census of approximately 160,000 patient visits. Within the community, there is a high degree of baseline hypertension and its associated cardiorenal complications. The eligible population included all adult patients presenting to the ED of either study site with severe decompensated heart failure. The diagnosis of severe decompensated heart failure was clinical and based on the presence of pulmonary rales, a portable chest radiograph determined by the treating physician to be consistent with pulmonary edema, and 1 or more of the following: a history of heart failure, tachypnea (respiratory rate [RR] 30 breaths/min), significant dyspnea (use of accessory muscles of respiration or obvious air hunger), and significant hypoxia (defined as oxygen saturation [SpO 2 ] 90% on room air or 95% on supplemental oxygen) or hypoxemia (partial pressure of arterial oxygen [PaO 2 ] 50 mm Hg on room air). To be considered for study inclusion, all of the following criteria had to be met: age greater than 18 years, a systolic blood pressure (SBP) greater than or equal to 160 mm Hg or mean arterial pressure greater than or equal to 120 mm Hg, and ability to obtain written informed consent from the patient or a close family member. Patients were excluded from study participation if they had any of the following: noncardiogenic pulmonary edema, requirement for immediate intubation or cardiopulmonary resuscitation, an inability to obtain informed consent because of alteration in cognition or consciousness or no family or alternative consenting source available, known or suspected pregnancy, acute ST-segment elevation myocardial infarction, suspected right-sided ventricular ischemia (STsegment depression or new T-wave inversions in leads V1 or V2), or known sensitivity or intolerance to sublingual, transdermal, or intravenous nitroglycerin. The study was approved by the Wayne State University institutional review board and human investigational committee. Patients who met the enrollment criteria were given a trial of initial therapy, which consisted of the following class I recommendations from the American Heart Association s 2000 Guidelines for the Evaluation and Management of Heart Failure : high-flow oxygen with a 100% nonrebreather mask, sublingual nitroglycerin tablets or oral mucosal spray at a dose of 0.4 mg every 5 minutes (maximum 4 treatments), and furosemide 60 to 80 mg by intravenous push. Morphine sulfate Volume 50, NO. 2 : August 2007 Annals of Emergency Medicine 145
3 Severe Decompensated Heart Failure Treated With Intravenous Nitroglycerin Levy et al 3- to 5-mg intravenous push was allowed but not required. Patients who improved in response to this regimen were no longer considered eligible for study inclusion. Patients who failed to improve and were believed to require intravenous nitroglycerin by the treating physician were approached and asked to participate by study personnel. All willing participants (or their family members) were informed of the study protocol, and written informed consent was obtained before study enrollment. Active patient screening was conducted for 18 consecutive months, from February 2003 through August During this time, a convenience sample of patients was recruited, the majority of whom (23 of 29) were enrolled at 1 site (Detroit Receiving Hospital) during the final 12 months (between July 2003 and August 2004). All enrolled patients had standard baseline information, including age, sex, underlying medical conditions, previous exacerbations or hospitalizations, cause of heart failure (if known), baseline New York Heart Association classification, and all current medications obtained and recorded. All patients underwent a routine physical examination, with particular attention on the presence and degree of rales on lung auscultation, presence of jugular venous distention, and the subjective level of dyspnea. Baseline automated SBP and diastolic blood pressure, mean arterial pressure, and pulse rate were obtained; pulse oximetry (SpO 2 ) and RR were also recorded. An ECG and a chest radiograph were performed, and blood samples were collected for routine analysis (including basic chemistry panel, CBC count, and cardiac biomarkers). The protocol also called for point-of-care brain-type natriuretic peptide testing (Triage brain-type natriuretic peptide; Biosite Diagnostics, San Diego, CA) for all patients, but because of logistic constraints, not all patients were tested. Interventions On initiation of the study protocol, all patients began receiving an intravenous nitroglycerin infusion at a starting dose of 0.3 to 0.5 g/kg per minute. Titration of the nitroglycerin infusion was allowed in increments of 20 g per minute every 1 to 3 minutes thereafter at the discretion of the treating emergency physician. The maximum rate of intravenous nitroglycerin infusion was fixed at 400 g per minute. Blood pressure (SBP, diastolic blood pressure, and mean arterial pressure), pulse rate, RR, and SpO 2 were recorded at the initiation of the trial and monitored continually throughout using either manual or automated devices. SBP less than 90 mm Hg was considered an absolute contraindication to intravenous nitroglycerin advancement, with abatement or termination of the infusion if hypotension persisted. Concurrent with the initiation of the nitroglycerin infusion, all patients received an initial 2-mg intravenous bolus of highdose nitroglycerin, which was prepared by diluting a standard nitroglycerin solution (American Reagent Laboratories, Inc, Shirley, NY) in 5% dextrose/water to a concentration of 1 mg/ ml. Subsequent 2-mg boluses of high-dose nitroglycerin were permitted every 3 to 5 minutes at the discretion of the treating emergency physician. Repeated administration of high-dose nitroglycerin was allowed for a period of up to 30 minutes, resulting in a maximum potential dose of 20 mg (2 mg every 3 minutes for 30 minutes). Study medication was administered in an open-label fashion. Ventilatory support with either endotracheal intubation or bilevel positive airway pressure (BiPAP) was permitted at any point during patient treatment. The decision to perform either endotracheal intubation or BiPAP was at the discretion of the treating emergency physician. Excessive decrease in blood pressure (defined as a reduction in SBP or mean arterial pressure 30%) was considered an indication to temporarily discontinue bolus treatment and diminish the rate of nitroglycerin infusion. Any episode that did not resolve spontaneously within 5 minutes or after a fluid bolus (500 ml of 0.9% normal saline solution) resulted in termination of the study protocol. Other indications for protocol termination included bradycardia (defined as a pulse rate 60 beats/min); new onset of chest pain, with ECG changes suggestive of developing myocardial ischemia or infarction (ST-segment elevation 1 mmor depression 2 mm in 2 contiguous leads or new left bundlebranch block) that was not present at protocol initiation; or new onset of neurologic deficits, as noted by the treating physician. Recommended treatment of these conditions was based on standard advanced cardiac life support protocols, but actual care was at the discretion of the treating emergency physician. Patients requiring further intensive care were admitted to a monitored unit bed, whereas hemodynamically stable and clinically improved patients were admitted to a general medical ward. Performance of an echocardiogram was requested for all enrolled patients during their inhospital stay, as was repeated testing of serum laboratory values at 24 and 48 hours postadmission. Ultimately, however, the treatment of the hospitalized patient was deferred to the admitting physician. Outcome Measures The primary effectiveness end point was the requirement for endotracheal intubation within the first 6 hours of treatment. The primary safety endpoints were development of either neurologic complications (defined as presence of any new speech, sensory, or movement deficits defined as a transient ischemic attacks or stroke on clinical grounds or by subsequent computed tomography of the brain) or cardiovascular complications, defined as hypotensive episodes requiring intervention or the incidence of acute myocardial infarction, as noted by immediate ECG changes as described or a positive troponin I test result (AxSYM by Abbott Laboratories, Abbott, IL) within 24 hours. Secondary endpoints included the following: proportion of patients requiring BiPAP, need for ICU admission, total hospital length of stay, interval development or worsening of renal dysfunction (as determined by increase in serum creatinine 146 Annals of Emergency Medicine Volume 50, NO. 2 : August 2007
4 Levy et al Severe Decompensated Heart Failure Treated With Intravenous Nitroglycerin Figure 1. Overview of patient recruitment. ADHF, Acute decompensated heart failure; DRH, Detroit Receiving Hospital; ETI, endotracheal intubation; SGH, Sinai-Grace Hospital. level 0.5 mg/dl at 24 or 48 hours), 30-day ED revisitation rate or hospital admission rate for decompensated heart failure, and interval changes in blood pressure (summated using mean arterial pressure), pulse rate, SpO 2, and RR. To provide an estimate of baseline outcomes in our study population, data were abstracted for a group of similar patients (n 45) who were treated for severe decompensated heart failure during the study recruitment period but were not enrolled in the trial (ie, did not receive high-dose nitroglycerin). Institutional review board approval with waiver of informed consent was obtained for retrospective analysis of the hospital records of these individuals, and only those patients who completely satisfied the inclusion/exclusion criteria were included. These data were abstracted by 2 study investigators, with double data entry to minimize entry errors. Because of sporadic enrollment during the initial 6 months of screening and an overall low rate of enrollment at one study site (Sinai- Grace Hospital), all nonintervention patients were derived from the cohort of individuals treated for severe decompensated heart failure without high-dose nitroglycerin at Detroit Receiving Hospital during the final 12 months of recruitment. Reasons for nonenrollment of these patients were not available. An outline of the patient recruitment scheme with more complete representation of group derivation is presented in Figure 1. Primary Data Analysis Baseline, treatment, and outcome variables are presented as means or proportions, with corresponding SDs, interquartile ranges, or 95% confidence intervals (CIs) where appropriate. Statistical analysis was performed with SPSS (version ; SPSS, Inc., Chicago, IL). Volume 50, NO. 2 : August 2007 Annals of Emergency Medicine 147
5 Severe Decompensated Heart Failure Treated With Intravenous Nitroglycerin Levy et al Table. Baseline data. Variable HDNTG (n 29) Nonintervention (n 45) Age, y, mean (SD) 61.4 (14.8) 64.9 (12.8) Male, % (95% CI) 65.5 ( ) 57.8 ( ) Black, % (95% CI) 89.7 ( ) 91.1 ( ) History, % (95% CI) CHF 89.7 ( ) 57.8 ( ) HTN 89.7 ( ) 80.0 ( ) CAD 37.9 ( ) 26.7 ( ) AMI 24.1 ( ) 24.4 ( ) Cigarettes 48.3 ( ) 33.3 ( ) Renal failure (dialysis) 20.7 ( ) 15.6 ( ) Current medications, % (95% CI) Angiotensin-converting 58.6 ( ) 53.3 ( ) enzyme inhibitors -Blockers 48.3 ( ) 44.4 ( ) ASA 27.6 ( ) 26.7 ( ) Diuretics 65.5 ( ) 42.2 ( ) NYHA Class% (95% CI) I ( ) II 20.7 ( ) 35.6 ( ) III 48.3 ( ) 40.0 ( ) IV 31.0 ( ) 17.8 ( ) NYHA III or IV 79.3 ( ) 57.8 ( ) BNP, mean (SD) (n 24) (n 9) 1,781.6 (2,683.0) 1,579.7 (2,757.1) Ejection fraction, mean (n 25) (n 42) (95% CI)* 35.7 ( ) ( ) Initial values, mean (SD) Mean arterial pressure (25.7) (24.5) Pulse rate (25.5) (22.4) RR 31.1 (6.7) 31.7 (7.7) Pulse oximetry 92.7 (5.4) 94.1 (6.4) HDNTG, High-dose nitroglycerin; CHF, congestive heart failure; HTN, hypertension; CAD, coronary artery disease; AMI, acute myocardial infarction; ASA, aspirin; NYHA, New York Heart Association; BNP, brain-type natriuretic peptide. *Ejection fraction expressed as percentage. RESULTS Characteristics of Study Subjects Baseline characteristics are presented in the Table. There was a high degree of preexisting hypertension in high-dose nitroglycerin (89.7%; 95% CI 74.9% to 97.0%) and nonintervention patients (80.0%; 95% CI 66.7% to 89.6%), but a history of coronary artery disease was relatively less common in both groups (37.9% [95% CI 22.1% to 56.1%] and 26.7% [95% CI 15.5% to 40.8%], respectively). Underlying heart failure was seen in a greater proportion of high-dose nitroglycerin patients (89.7%; 95% CI 74.9% to 97.0%) than nonintervention patients (57.8%; 95% CI 43.2% to 71.4%), with a suggestion of more advanced disease, as noted by a higher prevalence of New York Heart Association III or IV classification (79.3% [95% CI 62.2% to 90.9%] versus 57.8% [95% CI 43.2% to 71.4%]) and a lower mean ejection fraction (35.7% [95% CI 28.7% to 42.7%] versus 40.2% [95% CI 35.1% to 45.3%]). Patients in the high-dose nitroglycerin group were also receiving diuretics more frequently at baseline (65.5% [95% CI 47.4% to 80.7%] versus 42.2% [95% CI 28.7% to 56.8%]), but other baseline medications, including angiotensin-converting enzyme inhibitors and -blockers, were similar. Initial vital signs, including mean arterial pressure, pulse rate, RR, and SpO 2, were markedly abnormal in both intervention and nonintervention patients. Main Results The majority (34.5%) of patients received 3 boluses of highdose nitroglycerin (Figure 2), and the mean dose of high-dose nitroglycerin administered was 6.5 mg (95% CI 5.2 to 7.8 mg). The mean initial and final intravenous nitroglycerin infusion rates were 23.6 g/minute (95% CI 15.4 to 31.9 g/minute) and 50.2 (95% CI 37.9 to 62.5 g/minute) for patients who received high-dose nitroglycerin. The mean initial intravenous nitroglycerin infusion rate for the nonintervention group was 31.7 g/minute (95% CI 26.0 to 37.3 g/minute); the final intravenous nitroglycerin rate for nonintervention patients was not available. Mean furosemide dosing was 85.5 mg (95% CI 76.5 to 94.6 mg) in the high-dose nitroglycerin group and 82.1 mg (95% CI 72.8 to 91.4 mg) in the nonintervention group. -Blockers, angiotensin-converting enzyme inhibitors, and morphine were used in 10.3% (95% CI 3.0% to 25.1%), 34.5% (95% CI 19.3% to 52.6%), and 37.9% (95% CI 22.1% to 56.1%) of high-dose nitroglycerin patients and 11.1% (95% CI 4.4% to 22.7%), 11.1% (95% CI 4.4% to 22.7%), and 11.1% (95% CI 4.4% to 22.7%) of the nonintervention patients. The primary effectiveness endpoint of endotracheal intubation within 6 hours occurred in 13.8% (95% CI 4.8% to 29.5%) of patients treated with high-dose nitroglycerin and 26.7% (95% CI 15.5% to 40.8%) of the nonintervention patients. The primary safety endpoint of cardiovascular complications was 20.7% (95% CI 9.1% to 37.8%) in the high-dose nitroglycerin group (17.2% [95% CI 6.9% to 33.7%] with myocardial infarction and 3.5% [95% CI 0.4% to 15.0%] with symptomatic hypotension) and 28.9% (95% CI 17.3% to 43.1%) of the nonintervention patients (all due to myocardial infarction, with no episodes of symptomatic hypotension). There were no patients in either group who developed immediate ECG changes suggestive of cardiac ischemia during treatment, and all myocardial infarction diagnoses were based on interval development of biomarker positivity. Additionally, the occurrence of symptomatic hypotension in the high-dose nitroglycerin group corresponded to a single instance that developed after administration of one 2-mg dose and resolved with a 500-mL fluid bolus, without evidence of further complications. The other primary safety endpoint of adverse neurologic events was not witnessed in either group, and there were no inhospital deaths. Use of BiPAP occurred in 6.9% (95% CI 1.5% to 20.3%) of the high-dose nitroglycerin patients and 20.0% (95% CI 10.4% to 33.3%) of the nonintervention patients. The ICU admission rate was 37.9% (95% CI 22.1% to 56.1%) in the high-dose 148 Annals of Emergency Medicine Volume 50, NO. 2 : August 2007
6 Levy et al Severe Decompensated Heart Failure Treated With Intravenous Nitroglycerin Figure 2. Number of patients receiving high-dose nitroglycerin boluses by outcome. nitroglycerin group and 80.0% (95% CI 66.7% to 89.6%) in the nonintervention group. Mean total hospital length of stay was 4.1 days (95% CI 1.8 to 5.5 days) in high-dose nitroglycerin patients and 6.2 days (95% CI 3.9 to 8.6 days) in nonintervention patients. There was a similar degree of baseline renal dysfunction by mean serum creatinine level (normal at our institution 1.2 mg/dl) in both groups (high-dose nitroglycerin 3.5 mg/dl [95% CI 1.9 to 5.0 mg/dl]; nonintervention 2.8 mg/dl [95% CI 1.7 to 3.8 mg/dl]), with a similar incidence of creatinine increase within 48 hours (13.8% [95% CI 4.8% to 29.5%] for the high-dose nitroglycerin group and 15.6% [95% CI 7.2% to 28.1%] for the nonintervention group). Mean 30-day ED return visits for decompensated heart failure were also similar, occurring in 27.6% (95% CI 14.0% to 45.4%) and 22.2% (95% CI 12.0% to 35.9%) of high-dose nitroglycerin and nonintervention patients, respectively. Graphic display of the hemodynamic and respiratory response to high-dose nitroglycerin is presented in Figure 3A-D. Observations were available for the majority of patients during the first hour of treatment (median time from arrival [interquartile range] 55.0 minutes [48.0 to minutes]), with demonstrable improvements in mean arterial pressure, pulse rate, RR, and SpO 2. Though fewer data were available at points beyond this period, a continuation of the same trend was visible. The median (interquartile range) change between initial and final measurements for mean arterial pressure, pulse rate, RR, and SpO 2 were 50.0 mm Hg ( 33.2 to 75.0 mm Hg), 18 beats/min ( 7.5 to 37.0 beats/min), 8.0 beats/min ( 3.0 to 11.0 beats/min), and 3.0% (0.0% to 8.5%), respectively. Because we did not specify reassessment times for the nonintervention patients, similar data for that group were not available. LIMITATIONS Our study was limited by several important methodologic considerations. Foremost among these was the absence of a randomized design, which introduced the potential for selection bias and imbalances in group composition and disallowed powering the trial for clinical outcomes. Additionally, the retrospective nature of nonintervention group data collection precluded standardization and further limited our ability to perform direct comparison with high-dose nitroglycerin patients. Though retrospective analysis also increases the risk of recall bias and abstraction errors, our primary and secondary outcome measures were largely dichotomous and readily available from medical records, minimizing the potential for subjective interpretation. Furthermore, because the nonintervention patients were derived from a concurrent treatment pool, likelihood of confounding from seasonal or temporal variation in decompensated heart failure management was greatly reduced. Use of an open-label intervention was another important limitation that may have increased the potential for treatment bias. To partially account for this, we did follow patients throughout their hospital stay, during which time subsequent care was rendered by clinicians who had no vested interest in the study itself. Because patient enrollment was based in large part on the willingness of the noninvestigator ED staff to participate, it was thought that an open-label design would be appropriate for this preliminary study, enabling data collection for justification of a subsequent randomized, blinded trial. Last, this study had a relatively small sample size, with skewed ethnic representation. The limited number of patients enrolled is consistent with the preliminary nature of the trial, however, and, given the inherent difficulty of consenting procedures in the critically ill, was not entirely unanticipated. That nearly 90% of all those who participated in the study were blacks was also not surprising and is representative of the ethnic composition of the city of Detroit. Although this may limit the generalizability of our findings, it does add to the importance of our results because this is the only investigation of high-dose Volume 50, NO. 2 : August 2007 Annals of Emergency Medicine 149
7 Severe Decompensated Heart Failure Treated With Intravenous Nitroglycerin Levy et al Figure 3. Hemodynamic and respiratory response to high-dose nitroglycerin over time. A, Mean arterial pressure. B, Pulse rate. C, RR. D, SpO 2. nitrates to be conducted in a predominantly black patient population. DISCUSSION In this nonrandomized, open-label trial of treatment for hypertensive patients with severe decompensated heart failure, patients who received high-dose nitroglycerin required endotracheal intubation, BiPAP, or ICU admission with less frequency than patients who did not. Myocardial infarction was also less common among patients treated with high-dose nitroglycerin, but it is not clear whether this was an effect of the intervention or a result of baseline variability in group composition. Of particular importance, only 1 patient who received high-dose nitroglycerin developed symptomatic hypotension, and the incidence of induced renal impairment was low. This study was designed as a preliminary evaluation of high-dose nitroglycerin, with a single treatment arm; direct comparison with nonintervention patients therefore is not appropriate. Nonetheless, provision of data for patients treated 150 Annals of Emergency Medicine Volume 50, NO. 2 : August 2007
8 Levy et al Severe Decompensated Heart Failure Treated With Intravenous Nitroglycerin without high-dose nitroglycerin provides some measure of baseline outcomes in our study population and enables estimation of an effect size that can be used to power a future, methodologically more rigorous investigation. That we were able to enroll patients in this trial despite the critical nature of their illness is encouraging and implies that further research involving high-dose nitroglycerin is feasible. The pharmacologic basis for the proposed benefit of highdose nitroglycerin lies in the dose-dependent nature of the vascular response to nitrate therapy. At infusion doses of less than 250 g/minute, the effect of nitroglycerin is 24,25 predominantly venodilatory, resulting in preload reduction. For those patients with primarily systolic dysfunction, this may be helpful in restoring optimal cardiac contractile response to fluid overload. In markedly hypertensive patients, however, transient exacerbation of diastolic dysfunction may be the 5 principal mechanism responsible for decompenstation. This may be due, at least in part, to a physiologic increase in enddiastolic volume, which, in the setting of impaired ventricular compliance, results in an increase of diastolic pressure and fluid 5 backflow into the lungs (ie, cardiogenic pulmonary edema). In this setting, both preload and afterload reduction may be required to improve ventricular distensibility and ease the 26 pressure gradient impeding forward flow. Higher doses of intravenous nitroglycerin ( 250 g/minute) are known to induce both venous and arterial dilation, which may result in an augmented clinical response that exceeds either isolated effect. 24,25 Because the arterial response to nitroglycerin is more pronounced in patients with excessive vascular resistance, highdose nitroglycerin may be particularly advantageous for the treatment of severe decompensated heart failure patients with profound hypertension. 27 Effective reduction in mean arterial pressure ( 5% but 30%) within the first 30 minutes of treatment for patients with cardiogenic pulmonary edema has been shown to correlate with a decreased incidence of death, recurrent pulmonary edema, mechanical ventilation, and myocardial infarction during the subsequent 24 hours of treatment. Our findings are consistent with this and add to the existing body of literature supporting the use of high-dose nitrates for decompensated heart failure. The initial publication, an 28 observational study by Bosc et al, reported improvement in dyspnea and tachypnea in 71% of 35 patients treated with a single 3-mg bolus of intravenous nitroglycerin. Rabacal et al 22 followed this study with an analysis of high-dose isosorbide dinitrate (repeated 5- to 10-mg intravenous boluses) and noted marked symptom resolution in 68% of their patients (n 22), with a statistically significant reduction in blood pressure and increase in arterial ph. 20 Subsequent evaluations by Nashed et aland Nashed and Allegra 21 used repeated bolus doses of intravenous nitroglycerin (0.8 mg each) and found an 83% improvement in clinical condition in their sample of 24 patients. The largest analysis, by Cotter et al, 18 compared bolus 26 intravenous isosorbide dinitrate (3 mg intravenous every 5 minutes; n 56) with bolus intravenous furosemide treatment (80 mg intravenous every 15 minutes; n 54). An absolute reduction of 21% was reported in the composite endpoint of death, endotracheal intubation, or myocardial infarction and in the nitrate treated group. The mean total dose of isosorbide dinitrate in this study was 11.4 mg ( 6.8 mg) In the most recent evaluation, Sharon et al compared high-dose isosorbide dinitrate (4 mg intravenous every 4 minutes; n 20) with BiPAP (n 20) and found a significantly higher incidence of death, endotracheal intubation, or myocardial infarction in the BiPAP group (85% versus 25%; P.0003). As with our trial, the overall incidence of hypotension in these studies was low (0% to 13%), and there were no reports of additional adverse events. Although the preponderance of existing data on high-dose nitrates has been collected from patients who received isosorbide dinitrate, nitroglycerin and isosorbide dinitrate appear to function similarly through release of endogenous nitric oxide. Direct comparison of the 2 agents, however, has shown that intravenous nitroglycerin is approximately 8 times more potent than isosorbide dinitrate. 33,34 The relative nitrate doses used in our study, therefore, are far in excess of those reported from previous investigations. As such, we recommend caution in using high-dose nitroglycerin as described in this trial until more complete safety data are available. In conclusion, high-dose nitroglycerin was effective in this nonrandomized, open-label trial involving hypertensive, severely decompensated heart failure patients and was associated with a lower rate of endotracheal intubation, BiPAP, and ICU admission than non high-dose nitroglycerin treatment in clinically similar, retrospectively analyzed patients. A rapid and profound decrease in blood pressure was also observed with use of high-dose nitroglycerin, without an associated increase in adverse events. Though encouraging, these results are preliminary, and the next logical step in the evaluation of high-dose nitroglycerin is an adequately powered, multicenter, prospective, randomized, doubleblind, comparison trial. According to our investigation, conduction of such a trial seems feasible. Supervising editor: Allan B. Wolfson, MD Author contributions: PL conceived the study, supervised the conduction of the trial and all data collection, and drafted the article. PL, SC, RW, and RZ designed the trial and obtained grant funding. SC, RW, GD, AJ, RD, and RZ revised the article. GD, AJ, and RD assisted with conduction of the trial. GD, AJ, NP, and RD assisted with data collection. PL, SC, RW, NP, and RZ assisted with data analysis. PL takes responsibility for the paper as a whole. Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of Volume 50, NO. 2 : August 2007 Annals of Emergency Medicine 151
9 Severe Decompensated Heart Failure Treated With Intravenous Nitroglycerin Levy et al specific conflicts covered by this statement. Support provided by the Emergency Medicine Foundation. Publication dates: Received for publication January 5, Revisions received February 14, 2007, and February 20, Accepted for publication February 27, Available online May 23, Presented at the ACEP Scientific Assembly, September 2005, Washington, DC; and the SAEM Annual Meeting, May 2006, San Francisco, CA. Reprints not available from the authors. Address for correspondence: Phillip Levy, MD, MPH, Wayne State University Department of Emergency Medicine, 4201 St Antoine, UHC-6G, Detroit, MI 48201; , fax ; REFERENCES 1. Sacchetti A, Ramoska E, Moakes ME, et al. Effect of ED management on ICU use in acute pulmonary edema. Am J Emerg Med. 1999;17: Edoute Y, Roguin A, Behar D, et al. Prospective evaluation of pulmonary edema. Crit Care Med. 2000;28: Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287: Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41: Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344: Cotter G, Kaluski E, Moshkovitz Y, et al. Pulmonary edema: new insight on pathogenesis and treatment. Curr Opin Cardiol. 2001; 16: Summers RL, Parrott CW, Quale C, et al. Use of noninvasive hemodynamics to aid decision making in the initiation and titration of neurohormonal agents. Congest Heart Fail. 2004; 10(2 suppl 2): American Heart Association. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation. 1995;92: Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38: Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26: Hamilton RJ, Carter WA, Gallagher EJ. Rapid improvement of acute pulmonary edema with sublingual captopril. Acad Emerg Med. 1996;3: Pang D, Keenan SP, Cook DJ, et al. The effect of positive pressure airway support on mortality and the need for intubation in cardiogenic pulmonary edema: a systematic review. Chest. 1998;114: Levitt MA. A prospective, randomized trial of BiPAP in severe acute congestive heart failure. J Emerg Med. 2001;21: Peacock WF. Acute emergency department management of heart failure. Heart Fail Rev. 2003;8: Peacock F, Emerman C, Costanzo M, et al. Early initiation of intravenous vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE registry database [abstract]. Ann Emerg Med. 2003;42:s Bussmann WD, Schupp D. Effect of sublingual nitroglycerin in emergency treatment of severe pulmonary edema. Am J Cardiol. 1978;41: Armstrong PW, Armstrong JA, Marks GS. Pharmacokinetichemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. Circulation. 1980;62: Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of highdose isosorbide dinitrate plus low-dose furosemide versus highdose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351: Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002;4: Nashed AH, Allegra, JR, Eskin B, et al. Prospective trial of the treatment of acute cardiogenic pulmonary edema with IV nitroglycerin boluses. Ann Emerg Med. 1997;30: Nashed AH, Allegra JR. Intravenous nitroglycerin boluses in treating patients with cardiogenic pulmonary edema. Am J Emerg Med. 1995;13: Rabacal C, Ribeiro H, Nuno L, et al. The efficacy of isosorbide dinitrate administered in an intravenous bolus in acute cardiogenic pulmonary edema. Rev Port Cardiol. 1993;12: Sharon A, Shpirer I, Kaluski E, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol. 2000;36: Imhof PR, Ott B, Frankhauser P, et al. Difference in nitroglycerin dose-response in the venous and arterial beds. Eur J Clin Pharmacol. 1980;18: Herling IM. Intravenous nitroglycerin: clinical pharmacology and therapeutic considerations. Am Heart J. 1984;108: Cotter G, Moshkovitz Y, Kaluski E, et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail. 2003;5: Haber HL, Simek CL, Bergin JD, et al. Bolus intravenous nitroglycerin predominantly reduces afterload in patients with excessive arterial elastance. J Am Coll Cardiol. 1993;22: Bosc E, Bertinchant JP, Hertault J. The use of injectable nitroglycerin (a bolus of 3 mg) in the treatment of cardiogenic pulmonary edema. Ann Cardiol Angeiol (Paris). 1982;31: Gwilt DJ, Petri M, Reid DS. Intravenous isosorbide dinitrate in acute left ventricular failure a dose-response study. Eur Heart J. 1983;4: Ignarro LJ, Ross G, Tillisch J. Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. West J Med. 1991;154: Schneider W, Bussmann WD, Hartmann A, et al. Nitrate therapy in heart failure. Cardiologyr. 1991;79(suppl 2): Roth A, Weber L, Freidenberger L, et al. Hemodynamic effects of intravenous isosorbide dinitrate and nitroglycerine in acute myocardial infarction and elevated pulmonary artery wedge pressure. Chest. 1987;91: Muikku O, Hynynen M, Salmenpera M, et al. Vasodilator properties of nitroglycerin and isosorbide dinitrate during cardiopulmonary bypass. Br J Anaesth. 1992;68: Muikku O, Hynynen M, Salmenpera M, et al. Pulmonary vascular effects of nitroglycerin and isosorbide dinitrate in patients with end-stage cardiomyopathies. Acta Anaesthesiol Scand. 1996; 40(8 pt 1): Annals of Emergency Medicine Volume 50, NO. 2 : August 2007
Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationCurrent strategies for the prehospital care of congestive heart failure
Continuing Education OBJECTIVES Current strategies for the prehospital care of congestive heart failure by Bryan E. Bledsoe, DO, FACEP Upon completion of this article, the reader should be able to: Define
More informationRiociguat Clinical Trial Program
Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension
More informationUniversitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1
Test Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1 Heart Failure - Definition European Heart Journal (2008) 29, 2388 2442 Akute Herzinsuffizienz Diagnostik und
More informationACLS PRE-TEST ANNOTATED ANSWER KEY
ACLS PRE-TEST ANNOTATED ANSWER KEY June, 2011 Question 1: Question 2: There is no pulse with this rhythm. Question 3: Question 4: Question 5: Question 6: Question 7: Question 8: Question 9: Question 10:
More informationInpatient Heart Failure Management: Risks & Benefits
Inpatient Heart Failure Management: Risks & Benefits Dr. Kenneth L. Baughman Professor of Medicine Harvard Medical School Director, Advanced Heart Disease Section Brigham & Women's Hospital Harvard Medical
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationAtrial Fibrillation in the ICU: Attempting to defend 4 controversial statements
Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary
More informationACLS PHARMACOLOGY 2011 Guidelines
ACLS PHARMACOLOGY 2011 Guidelines ADENOSINE Narrow complex tachycardias or wide complex tachycardias that may be supraventricular in nature. It is effective in treating 90% of the reentry arrhythmias.
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationHeart Failure: Diagnosis and Treatment
Heart Failure: Diagnosis and Treatment Approximately 5 million people about 2 percent of the U.S. population are affected by heart failure. Diabetes affects 20.8 million Americans and 65 million Americans
More informationTreatment of cardiogenic shock
ACUTE HEART FAILURE AND COMORBIDITY IN THE ELDERLY Treatment of cardiogenic shock Christian J. Wiedermann, M.D., F.A.C.P. Associate Professor of Internal Medicine, Medical University of Innsbruck, Austria
More informationINTRODUCTION TO EECP THERAPY
INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and
More informationNon-Invasive Positive Pressure Ventilation in Heart Failure Patients: For Who, Wy & When?
REUNIÃO CONJUNTA DOS GRUPOS DE ESTUDO DE CUIDADOS INTENSIVOS CARDÍACOS E DE FISIOPATOLOGIA DO ESFORÇO E REABILITAÇÃO CARDÍACA O L H Ã O 2 7 e 2 8 d e J a n e i r o 2 0 1 2 Non-Invasive Positive Pressure
More informationSeptic Shock: Pharmacologic Agents for Hemodynamic Support. Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident
Septic Shock: Pharmacologic Agents for Hemodynamic Support Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident Objectives Define septic shock and briefly review pathophysiology Outline receptor
More informationCardiac Arrest - Ventricular Fibrillation / Pulseless Ventricular Tachycardia Protocol revised October 2008
Cardiac Arrest - Ventricular Fibrillation / Pulseless Ventricular Tachycardia Protocol revised October 2008 Preamble Survival from cardiorespiratory arrest for patients who present with ventricular fibrillation
More informationQuiz 5 Heart Failure scores (n=163)
Quiz 5 Heart Failure summary statistics The correct answers to questions are indicated by *. Students were awarded 2 points for question #3 for either selecting spironolactone or eplerenone. However, the
More informationIf you do not wish to print the entire pre-test you may print Page 2 only to write your answers, score your test, and turn in to your instructor.
This is a SAMPLE of the pretest you can access with your AHA PALS Course Manual at Heart.org/Eccstudent using your personal code that comes with your PALS Course Manual The American Heart Association strongly
More informationThe practice of lowering blood pressure (BP)
Original Paper Treatment of Hypertension in the Inpatient Setting: Use of Intravenous Labetalol and Hydralazine Alan B. Weder, MD; 1 Steven Erickson, PharmD 2 Acute blood pressure elevations are commonly
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationIt is recommended that the reader review each medical directive presented in this presentation along with the actual PCP Core medical directive.
It is recommended that the reader review each medical directive presented in this presentation along with the actual PCP Core medical directive. This presentation will highlight the changes and any new
More informationVasopressors. Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco
Vasopressors Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco Overview Define shock states Review drugs commonly used to treat hypotension
More informationCardiac Arrest Pediatric Ventricular Fibrillation / Pulseless Ventricular Tachycardia Protocol revised October 2008
Cardiac Arrest Pediatric Ventricular Fibrillation / Pulseless Ventricular Tachycardia Protocol revised October 2008 Preamble In contrast to cardiac arrest in adults, cardiopulmonary arrest in pediatric
More informationRISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department Sohil Pothiawala FAMS (EM), MRCSEd (A&E), M.Med (EM), MBBS Consultant Dept. of Emergency Medicine Singapore General Hospital
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationProcedure for Inotrope Administration in the home
Procedure for Inotrope Administration in the home Purpose This purpose of this procedure is to define the care used when administering inotropic agents intravenously in the home This includes: A. Practice
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationMedical Direction and Practices Board WHITE PAPER
Medical Direction and Practices Board WHITE PAPER Use of Pressors in Pre-Hospital Medicine: Proper Indication and State of the Science Regarding Proper Choice of Pressor BACKGROUND Shock is caused by a
More informationSummary and general discussion
Chapter 7 Summary and general discussion Summary and general discussion In this thesis, treatment of vitamin K antagonist-associated bleed with prothrombin complex concentrate was addressed. In this we
More informationJames F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
More informationIschemic Heart Disease: Angina Pectoris
Ischemic Heart Disease: Angina Pectoris Robert J. Straka, Pharm.D. FCCP Associate Professor University of Minnesota College of Pharmacy Minneapolis, Minnesota, USA strak001@umn.edu Learning Objectives
More informationInotropes/Vasoactive Agents Hina N. Patel, Pharm.D., BCPS Cathy Lawson, Pharm.D., BCPS
Inotropes/Vasoactive Agents Hina N. Patel, Pharm.D., BCPS Cathy Lawson, Pharm.D., BCPS 1. Definition -an agent that affects the contractility of the heart -may be positive (increases contractility) or
More informationAdding IV Amiodarone to the EMS Algorithm for Cardiac Arrest Due to VF/Pulseless VT
Adding IV Amiodarone to the EMS Algorithm for Cardiac Arrest Due to VF/Pulseless VT Introduction Before the year 2000, the traditional antiarrhythmic agents (lidocaine, bretylium, magnesium sulfate, procainamide,
More informationRemote Delivery of Cardiac Rehabilitation
Remote Delivery of Cardiac Rehabilitation Bonnie Wakefield, RN, PhD Kariann Drwal, MS Melody Scherubel, RN Thomas Klobucar, PhD Skyler Johnson, MS Peter Kaboli, MD, MS VA Rural Health Resource Center Central
More informationAddendum to Clinical Review for NDA 22-512
Addendum to Clinical Review for DA 22-512 Drug: Sponsor: Indication: Division: Reviewers: dabigatran (Pradaxa) Boehringer Ingelheim Prevention of stroke and systemic embolism in atrial fibrillation Division
More informationANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol
ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Isoproterenol Major Indications Status Asthmaticus As a last resort for
More informationRecommendations: Other Supportive Therapy of Severe Sepsis*
Recommendations: Other Supportive Therapy of Severe Sepsis* K. Blood Product Administration 1. Once tissue hypoperfusion has resolved and in the absence of extenuating circumstances, such as myocardial
More informationTACO vs. TRALI: Recognition, Differentiation, and Investigation of Pulmonary Transfusion Reactions
TACO vs. TRALI: Recognition, Differentiation, and Investigation of Pulmonary Transfusion Reactions Shealynn Harris, M.D. Assistant Medical Director American Red Cross Blood Services Southern Region Case
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationCH CONSCIOUS SEDATION
Summary: CH CONSCIOUS SEDATION It is the policy of Carondelet Health that moderate conscious sedation of patients will be undertaken with appropriate evaluation and monitoring. Effective Date: 9/4/04 Revision
More informationThe Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy
The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy Cindy Goodrich RN, MS, CCRN Content Description Sepsis is caused by widespread tissue injury and systemic inflammation resulting
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More information6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
More informationThe Role Of Early Stress Testing In Assessing Low Risk Chest Pain Patients Admitted Through The Emergency Department
The Role Of Early Stress Testing In Assessing Low Risk Chest Pain Patients Admitted Through The Emergency Department Simbo Chiadika LAY ABSTRACT A. Study purpose Cardiac stress testing has been recommended
More informationOfficial Online ACLS Exam
\ Official Online ACLS Exam Please fill out this form before you take the exam. Name : Email : Phone : 1. Hypovolemia initially produces which arrhythmia? A. PEA B. Sinus tachycardia C. Symptomatic bradyarrhythmia
More informationKING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTRE (GEN. ORG.) NURSING AFFAIRS. Scope of Service PEDIATRIC INTENSIVE CARE UNIT (PICU)
PICU-Jan.2012 Page 1 of 7 Number of Beds: 18 Nurse Patient Ratio: 1:1-2 : The Pediatric Intensive Care Unit (PICU) provides 24 hour intensive nursing care for patients aged neonate through adolescence.
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationEvaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies
Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies Michael A. Ross MD FACEP Associate Professor of Emergency Medicine Wayne State University School of Medicine Detroit
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationCHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)
CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99) March 2014 2014 MVP Health Care, Inc. CHAPTER 9 CHAPTER SPECIFIC CATEGORY CODE BLOCKS I00-I02 Acute rheumatic fever I05-I09 Chronic rheumatic heart
More informationPHSW Procedural Sedation Post-Test Answer Key. For the following questions, circle the letter of the correct answer(s) or the word true or false.
PHSW Procedural Sedation Post-Test Answer Key 1 1. Define Procedural (Conscious) Sedation: A medically controlled state of depressed consciousness where the patient retains the ability to continuously
More informationAktuelle Literatur aus der Notfallmedizin
05.02.2014 Aktuelle Literatur aus der Notfallmedizin prä- und innerklinisch Aktuelle Publikationen aus 2012 / 2013 PubMed hits zu emergency medicine 12,599 Abstract OBJECTIVES: Current American Heart
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Remit / Appraisal objective: Final scope To appraise the clinical and cost effectiveness of
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More information404 Section 5 Shock and Resuscitation. Scene Size-up. Primary Assessment. History Taking
404 Section 5 and Resuscitation Scene Size-up Scene Safety Mechanism of Injury (MOI)/ Nature of Illness (NOI) Ensure scene safety and address hazards. Standard precautions should include a minimum of gloves
More informationCardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias
Cardiovascular System & Its Diseases Lecture #4 Heart Failure & Cardiac Arrhythmias Dr. Derek Bowie, Department of Pharmacology & Therapeutics, Room 1317, McIntyre Bldg, McGill University derek.bowie@mcgill.ca
More informationRedefining the NSTEACS pathway in London
Redefining the NSTEACS pathway in London Sotiris Antoniou Consultant Pharmacist, Cardiovascular Medicine, Barts and The London NHS Trust and Project Lead, North East London Cardiovascular and Stroke Network
More informationCoronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
More informationType II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease
Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University
More informationHeart Disease: Diagnosis & Treatment
How I Treat Cardiology Peer Reviewed Heart Disease: Diagnosis & Treatment Amara Estrada, DVM, DACVIM (Cardiology) University of Florida Background Clinical heart disease is the stage of disease when a
More informationLow-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationAppendix L: HQO Year 1 Implementation Priorities
Appendix L: HQO Year 1 Implementation Priorities Chronic Obstructive Pulmonary Disease (Source: COPD Chairs) Non-Invasive Positive Pressure Ventilation Early Ambulation If possible, seek patient preferences
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationCardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
More informationProvision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine
Provision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine Guideline Updated: August 2010 Replaced: November 1998 To serve the public and guide the medical profession EDTA Chelation
More informationAfter acute myocardial infarction, diabetes CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS
CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS By Deborah Chyun, RN, PhD, Viola Vaccarino, MD, PhD, Jaime Murillo, MD, Lawrence H. Young, MD, and Harlan M. Krumholz,
More informationStatement on Disability: Pulmonary Hypertension
Statement on Disability: Pulmonary Hypertension Ronald J. Oudiz, MD and Robyn J. Barst, MD on behalf of Pulmonary Hypertension Association The Scientific Leadership Council of the Pulmonary Hypertension
More informationCardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease
Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease What is Cardiac Rehabilitation? Cardiac rehabilitation is a comprehensive exercise, education, and behavior modification
More informationNORTH WALES CRITICAL CARE NETWORK
NORTH WALES CRITICAL CARE NETWORK LEVELS OF CRITICAL CARE FOR ADULT PATIENTS Throughout the work of the North Wales Critical Care Network reference to Levels of Care for the critically ill are frequently
More informationAcute heart failure may be de novo or it may be a decompensation of chronic heart failure.
Management of Acute Left Ventricular Failure Acute left ventricular failure presents as pulmonary oedema due to increased pressure in the pulmonary capillaries. It is important to realise though that left
More informationAmerican Heart Association ACLS Pre-Course Self Assessment Dec., 2006. ECG Analysis. Name the following rhythms from the list below:
American Heart Association ACLS Pre-Course Self Assessment Dec., 2006 ECG Analysis This pre-test is exactly the same as the pretest on the ACLS Provider manual CD. This paper version can be completed in
More informationTarget groups: Paramedics, nurses, respiratory therapists, physicians, and others who manage respiratory emergencies.
Overview Estimated scenario time: 10 15 minutes Estimated debriefing time: 10 minutes Target groups: Paramedics, nurses, respiratory therapists, physicians, and others who manage respiratory emergencies.
More informationCoronary Heart Disease (CHD) Brief
Coronary Heart Disease (CHD) Brief What is Coronary Heart Disease? Coronary Heart Disease (CHD), also called coronary artery disease 1, is the most common heart condition in the United States. It occurs
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationMarilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL
Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT
More informationACLS Cardiac Arrest Algorithm Neumar, R. W. et al. Circulation 2010;122:S729-S767
ACLS Cardiac Arrest Algorithm Neumar, R. W. et al. Circulation 2010;122:S729-S767 Copyright 2010 American Heart Association ACLS Cardiac Arrest Circular Algorithm Neumar, R. W. et al. Circulation 2010;122:S729-S767
More informationREFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO
REFERRAL HOSPITAL The Importance of Door In Door Out Time DIDO Time to Treatment is critical for STEMI patients For patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary
More informationScottish Medicines Consortium
Scottish Medicines Consortium sildenafil citrate 20mg tablets (Revatio ) No. (235/06) Pfizer New indication 6 January 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationEfficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics
Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical
More informationGetting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot
Getting smart about dyspnea and life saving drug therapy in ACS patients Kobi George Kaplan Medical Center Rehovot 78 year old female Case description Presented with resting chest pain and dyspnea Co morbidities:
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationAdvanced Heart Failure & Transplantation Fellowship Program
Advanced Heart Failure & Transplantation Fellowship Program Curriculum I. Patient Care When on the inpatient Heart Failure and Transplant Cardiology service, the cardiology fellow will hold primary responsibility
More informationCardiac Arrest VF/Pulseless VT Learning Station Checklist
Cardiac Arrest VF/Pulseless VT Learning Station Checklist VF/VT 00 American Heart Association Adult Cardiac Arrest Shout for Help/Activate Emergency Response Epinephrine every - min Amiodarone Start CPR
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationCARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty
CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary
More informationSubject: Severe Sepsis/Septic Shock Published Date: August 9, 2013 Scope: Hospital Wide Original Creation Date: August 9, 2013
Stony Brook Medicine Severe Sepsis/Septic Shock Recognition and Treatment Protocols Subject: Severe Sepsis/Septic Shock Published Date: August 9, 2013 Scope: Hospital Wide Original Creation Date: August
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationA list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke
More informationThe patient s response to therapy within the first hour in the Emergency Room is one of the most reliable ways to predict need for hospitalization.
Emergency Room Asthma Management Algorithm The Emergency Room Asthma Management Algorithm is to be used for any patient seen in the Emergency Room with the diagnosis of asthma. (The initial history should
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationDepartment of Veterans Affairs VHA DIRECTIVE 2011-038 Veterans Health Administration Washington, DC 20420 November 2, 2011
Department of Veterans Affairs VHA DIRECTIVE 2011-038 Veterans Health Administration Washington, DC 20420 TREATMENT OF ACUTE ISCHEMIC STROKE (AIS) 1. PURPOSE: This Veterans Health Administration (VHA)
More informationCardiogenic shock: invasive and non-invasive monitoring John T. Parissis Attikon University Hospital Athens, Greece
Cardiogenic shock: invasive and non-invasive monitoring John T. Parissis Attikon University Hospital Athens, Greece Disclosures: Research grants by Abbott USA and Orion-Pharma as a member of steering committee
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationACLS Provider Manual Comparison Sheet Based on 2010 AHA Guidelines for CPR and ECC. BLS Changes
ACLS Provider Manual Comparison Sheet Based on 2010 AHA Guidelines for CPR and ECC CPR Chest compressions, Airway, Breathing (C-A-B) BLS Changes New Old Rationale New science indicates the following order:
More informationBCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:
More information